Dieses Schriftenverzeichnis listet die Publikationen in englischsprachigen Fachzeitschriften aller aktiven Mitglieder des gesamten Teams der Klinik für Infektiologie auf.
1. Stocker H, Kron F, Hartmann P, de With K, Addo M, Vehreschild M, Fatkenheuer G, Salzberger B, Sander LE, Rupp J: Caseload, clinical spectrum and economic burden of infectious diseases in patients discharged from hospitals in Germany. Infection 2025
2. Migaud P, Drauz D, Dalla Pria A, Hosmann K, Muller M, Ghaeni L, Stocker H: Hemophagocytic lymphohistiocytosis in people living with HIV-a single centre experience. Infection 2025, 53(5):2203–2207
3. Migaud P, Dalla Pria A, Hosmann K, Kelleher P, Fulgenzi CAM, Stocker H, Bower M: Haemophagocytic lymphohistiocytosis in HIV-associated HHV-8-positive multicentric Castleman disease. AIDS 2025, 39(5):519–525
4. Hillus D, Le NH, Tober-Lau P, Fietz AK, Hoffmann C, Stegherr R, Huang L, Baumgarten A, Voit F, Bickel M, Goldstein G, Wyen C, Stocker H, Wunsche T, Lee M, Schulbin H, Vallee M, Bohr U, Potthoff A, Cordes C, Isner C, Knox B, Carmona A, Stobaus N, Balicer R, Group SES, Kurth F, Sander LE: Safety and effectiveness of MVA-BN vaccination against mpox in at-risk individuals in Germany (SEMVAc and TEMVAc): a combined prospective and retrospective cohort study. Lancet Infect Dis 2025
5. Dayalan N, Leung S, Dahill K, Temple A, Somani N, Matos J, Mann S, Bracchi M, Nelson M, Bower M, Boffito M, Migaud P, Pria AD: Integrase inhibitors and paclitaxel for Kaposi sarcoma: Clinical relevance of pharmacological interaction. HIV Med 2025
6. Schneider S, Bergmann C, Becker F, Risse L, Isner C, Stocker H, Feufel MA, Rohrig A, Kurzai O, Lam TT, Hagel S, Pletz MW, Gastmeier P, Wiese-Posselt M: Teaching prudent antibiotic use on the go: a descriptive report on development, utilization and listener satisfaction of an educational podcast format for medical students and young professionals. Antimicrob Resist Infect Control 2024, 13(1):50
7. Migaud P, Naidenow J, Ghaeni L, Hosmann K, Kaghoma J, Kowomba J, Lubura V, Mabete D, Mvokolo S, Stocker H, Hartlapp I: Indicator-condition-guided HIV testing in rural DRC. Infection 2024, 52(3):1171–1174
8. Kaasch AJ, López-Cortés LE, Rodríguez-Baño J, Cisneros JM, Dolores Navarro M, Fätkenheuer G, Jung N, Rieg S, Lepeule R, Coutte L, Bernard L, Lemaignen A, Kösters K, MacKenzie CR, Soriano A, Hagel S, Fantin B, Lafaurie M, Talarmin J-P, Dinh A, Guimard T, Boutoille D, Welte T, Reuter S, Kluytmans J, Martin ML, Forestier E, Stocker H, Vitrat V, Tattevin P, Rommerskirchen A, Noret M, Adams A, Kern WV, Hellmich M, Seifert H, Valiente A, de Cueto M, Rodríguez Á, Molina J, Fischer J, Paul G, Gallien S, Fihman V, Lacasse M, Coustillères F, Becker C, Fuchs A, Morata L, Weis S, Ponscarme D, Khatchatourian L, Rouveix E, Merrien D, Lecomte R, Veenemans J, Vilchez HH, Kessel J, Bonten MJM, Rupp J, Hocqueloux L, Lucht F, Stahl J-P, Vlek A, Prinz-Langenohl R, Tolsma V: Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial. The Lancet Infectious Diseases 2024
9. Hentrich M, Muller M, Wyen C, Pferschy A, Jurinovic V, Siehl J, Rockstroh JK, Schurmann D, Hoffmann C, German HIVRLSG: Stage-adapted treatment of HIV-associated Hodgkin lymphoma: Long-term results of a prospective, multicenter study. Hemasphere 2024, 8(7):e68
10. Riebold D, Mahnkopf M, Wicht K, Zubiria-Barrera C, Heise J, Frank M, Misch D, Bauer T, Stocker H, Slevogt H: Axenic Long-Term Cultivation of Pneumocystis jirovecii. J Fungi (Basel) 2023, 9(9)
11. Migaud P, Hosmann K, Drauz D, Mueller M, Haumann J, Stocker H: A case of occupational transmission of mpox. Infection 2023:1–5
12. Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, Palich R, Nori A, Reeves I, Habibi MS, Apea V, Boesecke C, Vandekerckhove L, Yakubovsky M, Sendagorta E, Blanco JL, Florence E, Moschese D, Maltez FM, Goorhuis A, Pourcher V, Migaud P, Noe S, Pintado C, Maggi F, Hansen AE, Hoffmann C, Lezama JI, Mussini C, Cattelan A, Makofane K, Tan D, Nozza S, Nemeth J, Klein MB, Orkin CM: Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022. The New England journal of medicine 2022
13. Müller M, Ingold-Heppner B, Stocker H, Heppner FL, Dittmayer C, Laue M: Electron microscopy images of monkeypox virus infection in 24-year-old man. Lancet (London, England) 2022, 400(10363):1618
14. Migaud P, Müller M, Arastéh K, Hentrich M, Stocker H: Hemophagocytic lymphohistiocytosis in HIV-associated lymphoproliferative disorders. Annals of hematology 2022, 101(10):2281–2287
15. Tominski D, Hosmann K, Yilmaz A: New Diagnosis of HIV in Case of Sepsis Caused by Streptococcus pyogenes. Dtsch Arztebl Int 2021, 118(47):813
16. Hentrich M, Muller M, Wyen C, Bogner J, Thomssen H, Wasmuth JC, Wolf T, Hoffmann C, Schommers P: Characteristics and outcome of human immunodeficiency virus (HIV)-associated primary effusion lymphoma as observed in the German HIV-related lymphoma cohort study. Br J Haematol 2021, 194(3):642–646
17. Stocker H, Mehlhorn C, Jordan K, Eckholt L, Jefferys L, Arastéh K: Clinical and economic effects of an antimicrobial stewardship intervention in a surgical intensive care unit. Infection 2020, 48(4):509–519
18. Buchholz U, Jahn HJ, Brodhun B, Lehfeld AS, Lewandowsky MM, Reber F, Adler K, Bochmann J, Förster C, Koch M, Schreiner Y, Stemmler F, Gagell C, Harbich E, Bärwolff S, Beyer A, Geuß-Fosu U, Hänel M, Larscheid P, Murajda L, Morawski K, Peters U, Pitzing R, von Welczeck A, Widders G, Wischnewski N, Abdelgawad I, Hinzmann A, Hedeler D, Schilling B, Schmidt S, Schumacher J, Zuschneid I, Atmowihardjo I, Arastéh K, Behrens S, Creutz P, Elias J, Gregor M, Kahl S, Kahnert H, Kimmel V, Lehmke J, Migaud P, Mikolajewska A, Moos V, Naumann MB, Pankow W, Scherübl H, Schmidt B, Schneider T, Stocker H, Suttorp N, Thiemig D, Gollnisch C, Mannschatz U, Haas W, Schaefer B, Lück C: Source attribution of community-acquired cases of Legionnaires' disease-results from the German LeTriWa study; Berlin, 2016-2019. PloS one 2020, 15(11):e0241724
19. Lemoine M, Assoumou L, De Wit S, Girard PM, Valantin MA, Katlama C, Necsoi C, Campa P, Huefner AD, Schulze Zur Wiesch J, Rougier H, Bastard JP, Stocker H, Mauss S, Serfaty L, Ratziu V, Menu Y, Schlue J, Behrens G, Bedossa P, Capeau J, Ingiliz P, Costagliola D, Group A-E: Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study. J Acquir Immune Defic Syndr 2019, 80(4):e86–e94
20. Schommers P, Gillor D, Hentrich M, Wyen C, Wolf T, Oette M, Zoufaly A, Wasmuth JC, Bogner JR, Muller M, Esser S, Schleicher A, Jensen B, Stoehr A, Behrens G, Schultze A, Siehl J, Thoden J, Taylor N, Hoffmann C: Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study. Haematologica 2018, 103(5):857–864
21. Tominski D, Katchanov J, Driesch D, Daley MB, Liedtke A, Schneider A, Slevogt H, Arasteh K, Stocker H: The late-presenting HIV-infected patient 30 years after the introduction of HIV testing: spectrum of opportunistic diseases and missed opportunities for early diagnosis. HIV Med 2017, 18(2):125–132
22. Steininger K, Boyd A, Dupke S, Krznaric I, Carganico A, Munteanu M, Neifer S, Schuetze M, Obermeier M, Arasteh K, Baumgarten A, Ingiliz P: HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C. J Viral Hepat 2017, 24(10):832–839
23. Bourgeois S, Van Vlierberghe H, Moreno C, Orlent H, Nevens F, Arasteh K, Horsmans Y, Schattenberg JM, Buggisch P, Francque S, Vijgen L, Kakuda TN, Hoeben E, Luo D, Vandebosch A, Jacquemyn B, Van Remoortere P, Verloes R: Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection. BMC Gastroenterol 2017, 17(1):26
24. Katchanov J, Wostmann K, Tominski D, Jefferys L, Liedtke A, Schneider A, Slevogt H, Arasteh K, Stocker H: Burden and spectrum of infectious disease in Germany 2009-2014: a multicentre study from Berlin's Municipal Hospitals. Infection 2016, 44(2):187–195
25. Katchanov J, Branding G, Jefferys L, Arasteh K, Stocker H, Siebert E: Neuroimaging of HIV-associated cryptococcal meningitis: comparison of magnetic resonance imaging findings in patients with and without immune reconstitution. Int J STD AIDS 2016, 27(2):110–117
26. Hoffmann C, Schommers P, Wolf E, Muller M, Schultze A, Krznaric I, Stoehr A, Wolf T, Faktenheuer G, Stier B, Wyen C, Hentrich M: CD4+ and CD8+ T-cell kinetics in aviremic HIV-infected patients developing Hodgkin or non-Hodgkin lymphoma. AIDS 2016, 30(5):753–760
27. Cooper DA, Cordery DV, Zajdenverg R, Ruxrungtham K, Arasteh K, Bergmann F, Neto JL, Scherer J, Chaves RL, Robinson P, study t: Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naive HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial. PloS one 2016, 11(1):e0144917
28. Soliman EZ, Sharma S, Arasteh K, Wohl D, Achhra A, Tambussi G, O'Connor J, Stein JH, Duprez DA, Neaton JD, Phillips A, International Network for Strategic Initiatives in Global HIVTSSG: Baseline cardiovascular risk in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015, 16 Suppl 1:46–54
29. Schommers P, Hentrich M, Hoffmann C, Gillor D, Zoufaly A, Jensen B, Bogner JR, Thoden J, Wasmuth JC, Wolf T, Oette M, Muller M, Esser S, Vehreschild JJ, Fatkenheuer G, Wyen C: Survival of AIDS-related diffuse large B-cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV Lymphoma Cohort. Br J Haematol 2015, 168(6):806–810
30. Raffi F, Rachlis A, Brinson C, Arasteh K, Gorgolas M, Brennan C, Pappa K, Almond S, Granier C, Nichols WG, Cuffe RL, Eron J, Jr., Walmsley S: Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials. AIDS 2015, 29(2):167–174
31. Katchanov J, Jefferys L, Tominski D, Wostmann K, Slevogt H, Arasteh K, Stocker H: Cryptococcosis in HIV-infected hospitalized patients in Germany: Evidence for routine antigen testing. J Infect 2015, 71(1):110–116
32. Katchanov J, Blechschmidt C, Nielsen K, Branding G, Arasteh K, Tintelnot K, Meintjes G, Boulware DR, Stocker H: Cryptococcal meningoencephalitis relapse after an eight-year delay: an interplay of infection and immune reconstitution. Int J STD AIDS 2015, 26(12):912–914
33. Hoffmann C, Hentrich M, Gillor D, Behrens G, Jensen B, Stoehr A, Esser S, van Lunzen J, Krznaric I, Muller M, Oette M, Hensel M, Thoden J, Fatkenheuer G, Wyen C: Hodgkin lymphoma is as common as non-Hodgkin lymphoma in HIV-positive patients with sustained viral suppression and limited immune deficiency: a prospective cohort study. HIV Med 2015, 16(4):261–264
34. Gallant JE, Koenig E, Andrade-Villanueva JF, Chetchotisakd P, DeJesus E, Antunes F, Arasteh K, Rizzardini G, Fehr J, Liu HC, Abram ME, Cao H, Szwarcberg J: Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results. J Acquir Immune Defic Syndr 2015, 69(3):338–340
35. Dieterich D, Nelson M, Soriano V, Arasteh K, Guardiola JM, Rockstroh JK, Bhagani S, Laguno M, Tural C, Ingiliz P, Jain MK, Stern JO, Manero M, Vinisko R, Kort J, group STs: Faldaprevir and pegylated interferon alpha-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV. AIDS 2015, 29(5):571–581
36. Stellbrink HJ, Arasteh K, Schurmann D, Stephan C, Dierynck I, Smyej I, Hoetelmans RM, Truyers C, Meyvisch P, Jacquemyn B, Marien K, Simmen K, Verloes R: Antiviral activity, pharmacokinetics, and safety of the HIV-1 protease inhibitor TMC310911, coadministered with ritonavir, in treatment-naive HIV-1-infected patients. J Acquir Immune Defic Syndr 2014, 65(3):283–289
37. Katchanov J, Zimmermann U, Branding G, Tintelnot K, Muller M, Arasteh K, Stocker H: Multiphasic and multifocal cryptococcal immune reconstitution inflammatory syndrome in an HIV-infected patient: interplay of infection and immunity. Int J Infect Dis 2014, 18:87–89
38. Katchanov J, Zimmermann U, Branding G, Arasteh K, Muller M: HIV-associated multicentric Castleman's disease after initiation of antiretroviral therapy: experience of a European centre. Infection 2014, 42(4):791–793
39. Katchanov J, von Kleist M, Arasteh K, Stocker H: 'Time-to-amphotericin B' in cryptococcal meningitis in a European low-prevalence setting: analysis of diagnostic delays. QJM 2014
40. Katchanov J, Branding G, Stocker H: Combined CMV- and HSV-1 brainstem encephalitis restricted to medulla oblongata. J Neurol Sci 2014, 339(1-2):229–230
41. Ingiliz P, Krznaric I, Stellbrink HJ, Knecht G, Lutz T, Noah C, Stocker H, Obermeier M, Dupke S, Boesecke C, Rockstroh JK, Baumgarten A, Hoffmann C: Multiple hepatitis C virus (HCV) reinfections in HIV-positive men who have sex with men: no influence of HCV genotype switch or interleukin-28B genotype on spontaneous clearance. HIV Med 2014, 15(6):355–361
42. Hentrich M, Hoffmann C, Mosthaf F, Muller M, Siehl J, Wyen C, Hensel M, German Study Group of Physicians in Private Practice Treating HIVIP, German AS: Therapy of HIV-associated lymphoma-recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNA), in cooperation with the German AIDS Society (DAIG). Annals of hematology 2014, 93(6):913–921
43. Harrer T, Plettenberg A, Arasteh K, Van Lunzen J, Fatkenheuer G, Jaeger H, Janssens M, Burny W, Collard A, Roman F, Loeliger A, Koutsoukos M, Bourguignon P, Lavreys L, Voss G: Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled study. Vaccine 2014, 32(22):2657–2665
44. Arribas J, Rizzardini G, Arasteh K, Zurawski C, Dietz C, Pontani D, Garner W, Nguyen T: Simplification to Stribild vs continuation of RTV-boosted DRV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-PI subgroup analysis. J Int AIDS Soc 2014, 17(4 Suppl 3):19805
45. Zeuzem S, Asselah T, Angus P, Zarski JP, Larrey D, Mullhaupt B, Gane E, Schuchmann M, Lohse AW, Pol S, Bronowicki JP, Roberts S, Arasteh K, Zoulim F, Heim M, Stern JO, Nehmiz G, Kukolj G, Bocher WO, Mensa FJ: Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results. Antivir Ther 2013, 18(8):1015–1019
46. Larrey D, Lohse AW, Trepo C, Bronowicki JP, Arasteh K, Bourliere M, Calleja JL, Stern JO, Nehmiz G, Abdallah N, Berger KL, Marquis M, Steffgen J, Kukolj G: Antiviral effect, safety, and pharmacokinetics of five-day oral administration of Deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in patients with chronic hepatitis C. Antimicrob Agents Chemother 2013, 57(10):4727–4735
47. Katchanov J, Branding G, Stocker H: Central pontine myelinolysis in advanced HIV infection with tuberculosis and multicentric Castleman's disease. Int J STD AIDS 2013, 24(7):583–584
48. Gallant JE, Koenig E, Andrade-Villanueva J, Chetchotisakd P, DeJesus E, Antunes F, Arasteh K, Moyle G, Rizzardini G, Fehr J, Liu Y, Zhong L, Callebaut C, Szwarcberg J, Rhee MS, Cheng AK: Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results. J Infect Dis 2013, 208(1):32–39
49. Wyen C, Jensen B, Hentrich M, Siehl J, Sabranski M, Esser S, Gillor D, Muller M, Van Lunzen J, Wolf T, Bogner JR, Wasmuth JC, Christ H, Fatkenheuer G, Hoffmann C: Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients. AIDS 2012, 26(4):457–464
50. Larrey D, Lohse AW, de Ledinghen V, Trepo C, Gerlach T, Zarski JP, Tran A, Mathurin P, Thimme R, Arasteh K, Trautwein C, Cerny A, Dikopoulos N, Schuchmann M, Heim MH, Gerken G, Stern JO, Wu K, Abdallah N, Girlich B, Scherer J, Berger F, Marquis M, Kukolj G, Bocher W, Steffgen J: Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. J Hepatol 2012, 57(1):39–46
51. Hodder S, Arasteh K, De Wet J, Gathe J, Gold J, Kumar P, Mohapi L, Short W, Crauwels H, Vanveggel S, Boven K: Effect of gender and race on the week 48 findings in treatment-naive, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. HIV Med 2012, 13(7):406–415
52. Hentrich M, Berger M, Wyen C, Siehl J, Rockstroh JK, Muller M, Fatkenheuer G, Seidel E, Nickelsen M, Wolf T, Rieke A, Schurmann D, Schmidmaier R, Planker M, Alt J, Mosthaf F, Engert A, Arasteh K, Hoffmann C: Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. J Clin Oncol 2012, 30(33):4117–4123
53. Arasteh K, Ward D, Plettenberg A, Livrozet JM, Orkin C, Cordes C, Guo J, Wang E, Yong CL, Robinson P, Quinson A: Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION). HIV Med 2012, 13(4):236–244
54. Zeuzem S, Asselah T, Angus P, Zarski JP, Larrey D, Mullhaupt B, Gane E, Schuchmann M, Lohse A, Pol S, Bronowicki JP, Roberts S, Arasteh K, Zoulim F, Heim M, Stern JO, Kukolj G, Nehmiz G, Haefner C, Boecher WO: Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology 2011, 141(6):2047–2055; quiz e2014
55. von Kleist M, Menz S, Stocker H, Arasteh K, Schutte C, Huisinga W: HIV quasispecies dynamics during pro-active treatment switching: impact on multi-drug resistance and resistance archiving in latent reservoirs. PloS one 2011, 6(3):e18204
56. Soriano V, Arasteh K, Migrone H, Lutz T, Opravil M, Andrade-Villanueva J, Antunes F, Di Perri G, Podzamczer D, Taylor S, Domingo P, Gellermann H, de Rossi L: Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. Antivir Ther 2011, 16(3):339–348
57. Marretta L, Stocker H, Drauz D, Mueller M, Masuhr A, Dieckmann S, Wong V, Koch A, Grueneisen A, Arasteh K, Weiss R: Treatment of HIV-related primary central nervous system lymphoma with AZT high dose, HAART, interleukin-2 and foscarnet in three patients. Eur J Med Res 2011, 16(5):197–205
58. Hoffmann C, Schmid H, Muller M, Teutsch C, van Lunzen J, Esser S, Wolf T, Wyen C, Sabranski M, Horst HA, Reuter S, Vogel M, Jager H, Bogner J, Arasteh K: Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease. Blood 2011, 118(13):3499–3503
59. Cooper DA, Cordery DV, Reiss P, Henry K, Nelson M, O'Hearn M, Reynes J, Arasteh K, Chung J, Rowell L, Guimaraes D, Bertasso A: The effects of enfuvirtide therapy on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudy. HIV Med 2011, 12(1):31–39
60. Battegay M, Arasteh K, Plettenberg A, Bogner JR, Livrozet JM, Witt MD, Mossdorf E, Yong CL, Zhang W, Macha S, Berger F, Stern J, Robinson P, Quinson AM: Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study. Clin Ther 2011, 33(9):1308–1320
61. Herzmann C, Arasteh K: Efavirenz-induced osteomalacia. AIDS 2009, 23(2):274–275
62. Arasteh K, Yeni P, Pozniak A, Grinsztejn B, Jayaweera D, Roberts A, Hoy J, De Meyer S, Vangeneugden T, Tomaka F: Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antivir Ther 2009, 14(6):859–864
63. Arasteh K, Weitner L, Fenske S, Kuhlmann B, Freiwald M, Ebrahimi R, Gallo L, Ranneberg R, Mertenskoetter T: Switch from a ZDV/3TC-based regimen to a completely once daily (QD) regimen of emtricitabine/tenofovir DF fixed dose combination plus a third QD agent (SONETT). Eur J Med Res 2009, 14(5):195–199
64. Arasteh K, Rieger A, Yeni P, Pozniak A, Boogaerts G, van Heeswijk R, de Bethune MP, Peeters M, Woodfall B: Short-term randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapy. Antivir Ther 2009, 14(5):713–722
65. Traeder C, Kowoll S, Arasteh K: Candida infection in HIV positive patients 1985-2007. Mycoses 2008, 51 Suppl 2:58–61
66. Steiner B, Kupsch A, Siebert E, Hosmann K, Klempin F, Morgenstern R, Winter C: Unilateral lesion of the subthalamic nucleus transiently provokes bilateral subacute glial cell proliferation in the adult rat substantia nigra. Neurosci Lett 2008, 430(2):103–108
67. Schulbin H, Bode H, Stocker H, Schmidt W, Zippel T, Loddenkemper C, Engelmann E, Epple HJ, Arasteh K, Zeitz M, Ullrich R: Cytokine expression in the colonic mucosa of human immunodeficiency virus-infected individuals before and during 9 months of antiretroviral therapy. Antimicrob Agents Chemother 2008, 52(9):3377–3384
68. Kakuda TN, Scholler-Gyure M, Workman C, Arasteh K, Pozniak AL, De Smedt G, Beets G, Peeters M, Vandermeulen K, Woodfall BJ, Hoetelmans RM: Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients. Antivir Ther 2008, 13(5):655–661
69. van Lunzen J, Liess H, Arasteh K, Walli R, Daut B, Schurmann D: Concomitant use of gastric acid-reducing agents is frequent among HIV-1-infected patients receiving protease inhibitor-based highly active antiretroviral therapy. HIV Med 2007, 8(4):220–225
70. Stocker H, Herzmann C, Breske A, Kruse G, Berger M, Schulbin H, Hill A, Steinmuller J, Becker M, Arasteh K, Kurowski M: Saquinavir, nelfinavir and M8 pharmacokinetics following combined saquinavir, ritonavir and nelfinavir administration. J Antimicrob Chemother 2007, 59(3):560–564
71. Rittweger M, Arasteh K: Clinical pharmacokinetics of darunavir. Clin Pharmacokinet 2007, 46(9):739–756
72. Reynes J, Arasteh K, Clotet B, Cohen C, Cooper DA, Delfraissy JF, Eron JJ, Henry K, Katlama C, Kuritzkes DR, Lalezari JP, Lange J, Lazzarin A, Montaner JS, Nelson M, M OH, Stellbrink HJ, Trottier B, Walmsley SL, Buss NE, Demasi R, Chung J, Donatacci L, Guimaraes D, Rowell L, Valentine A, Wilkinson M, Salgo MP: TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. AIDS Patient Care STDS 2007, 21(8):533–543
73. Kurowski M, Walli RK, Breske A, Kruse G, Stocker H, Banik N, Richter H, Mazur D: Fosamprenavir/ritonavir plus tenofovir does not affect amprenavir pharmacokinetics: no effect of tenofovir. AIDS 2007, 21(10):1368–1370
74. Gathe JC, Jr., Pierone G, Piliero P, Arasteh K, Rubio R, Lalonde RG, Cooper D, Lazzarin A, Kohlbrenner VM, Dohnanyi C, Sabo J, Mayers D: Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients. AIDS Res Hum Retroviruses 2007, 23(2):216–223
75. Arasteh K, Stocker H: Tropism switch in patients infected with HIV-1 and its clinical implications for the treatment with CCR5-receptor inhibitors. Eur J Med Res 2007, 12(9):397–402
76. Winter C, Hosmann K, Harnack D, Meissner W, Paul G, Morgenstern R, Kupsch A: Subthalamic nucleus lesioning inhibits expression and phosphorylation of c-Jun in nigral neurons in the rat's 6-OHDA model of Parkinson's disease. Synapse 2006, 60(1):69–80
77. Weiss R, Mitrou P, Arasteh K, Schuermann D, Hentrich M, Duehrsen U, Sudeck H, Schmidt-Wolf IG, Anagnostopoulos I, Huhn D: Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival--results of the German Multicenter Trial. Cancer 2006, 106(7):1560–1568
78. von Hentig N, Carlebach A, Gute P, Knecht G, Klauke S, Rohrbacher M, Stocker H, Kurowski M, Harder S, Staszewski S, Haberl A: A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy. Br J Clin Pharmacol 2006, 62(5):552–559
79. Stocker H, Kloft C, Plock N, Breske A, Kruse G, Herzmann C, Schulbin H, Kreckel P, Weber C, Goebel F, Roeling J, Staszewski S, Plettenberg A, Moecklinghoff C, Arasteh K, Kurowski M: Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings. Antimicrob Agents Chemother 2006, 50(2):667–673
80. Hentrich M, Maretta L, Chow KU, Bogner JR, Schurmann D, Neuhoff P, Jager H, Reichelt D, Vogel M, Ruhnke M, Oette M, Weiss R, Rockstroh J, Arasteh K, Mitrou P: Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study. Ann Oncol 2006, 17(6):914–919
81. Cahn P, Villacian J, Lazzarin A, Katlama C, Grinsztejn B, Arasteh K, Lopez P, Clumeck N, Gerstoft J, Stavrianeas N, Moreno S, Antunes F, Neubacher D, Mayers D: Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin Infect Dis 2006, 43(10):1347–1356
82. Weitzel T, Muhlberger N, Jelinek T, Schunk M, Ehrhardt S, Bogdan C, Arasteh K, Schneider T, Kern WV, Fatkenheuer G, Boecken G, Zoller T, Probst M, Peters M, Weinke T, Gfrorer S, Klinker H, Holthoff-Stich ML: Imported leishmaniasis in Germany 2001-2004: data of the SIMPID surveillance network. Eur J Clin Microbiol Infect Dis 2005, 24(7):471–476
83. Trottier B, Walmsley S, Reynes J, Piliero P, O'Hearn M, Nelson M, Montaner J, Lazzarin A, Lalezari J, Katlama C, Henry K, Cooper D, Clotet B, Arasteh K, Delfraissy JF, Stellbrink HJ, Lange J, Kuritzkes D, Eron JJ, Jr., Cohen C, Kinchelow T, Bertasso A, Labriola-Tompkins E, Shikhman A, Atkins B, Bourdeau L, Natale C, Hughes F, Chung J, Guimaraes D, Drobnes C, Bader-Weder S, Demasi R, Smiley L, Salgo MP: Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr 2005, 40(4):413–421
84. Nelson M, Arasteh K, Clotet B, Cooper DA, Henry K, Katlama C, Lalezari JP, Lazzarin A, Montaner JS, O'Hearn M, Piliero PJ, Reynes J, Trottier B, Walmsley SL, Cohen C, Eron JJ, Jr., Kuritzkes DR, Lange J, Stellbrink HJ, Delfraissy JF, Buss NE, Donatacci L, Wat C, Smiley L, Wilkinson M, Valentine A, Guimaraes D, Demasi R, Chung J, Salgo MP: Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005, 40(4):404–412
85. Lichterfeld M, Qurishi N, Hoffmann C, Hochdorfer B, Brockmeyer NH, Arasteh K, Mauss S, Rockstroh JK: Treatment of HIV-1-associated Kaposi's sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery. Infection 2005, 33(3):140–147
86. Kruse G, Esser S, Stocker H, Breske A, Koerber A, Kopperman M, Wiehler H, Ross B, Mocklinghoff C, Hill A, Becker M, Kurowski M: The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients. Antivir Ther 2005, 10(2):349–355
87. Johnson M, Nieto-Cisneros L, Horban A, Arasteh K, Gonzalez-Garcia J, Artigas JG, Clotet B, Danise A, Landman R, Proll S, Snowden W, Foreman R, Smith P: Comparison of gastrointestinal tolerability and patient preference for treatment with the 625 mg and 250 mg nelfinavir tablet formulations. HIV Med 2005, 6(2):107–113
88. Herzmann C, Arasteh K, Murphy RL, Schulbin H, Kreckel P, Drauz D, Schinazi RF, Beard A, Cartee L, Otto MJ: Safety, pharmacokinetics, and efficacy of (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine with efavirenz and stavudine in antiretroviral-naive human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2005, 49(7):2828–2833
89. Arasteh K, Clumeck N, Pozniak A, Lazzarin A, De Meyer S, Muller H, Peeters M, Rinehart A, Lefebvre E: TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial. AIDS 2005, 19(9):943–947
90. Wood R, Eron J, Arasteh K, Teofilo E, Trepo C, Livrozet JM, Yeo J, Millard J, Wire MB, Naderer OJ: A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of HIV-infected patients. Clin Infect Dis 2004, 39(4):591–594
91. Wood R, Arasteh K, Stellbrink HJ, Teofilo E, Raffi F, Pollard RB, Eron J, Yeo J, Millard J, Wire MB, Naderer OJ: Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother 2004, 48(1):116–123
92. Stocker H, Kruse G, Kreckel P, Herzmann C, Arasteh K, Claus J, Jessen H, Cordes C, Hintsche B, Schlote F, Schneider L, Kurowski M: Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004, 48(11):4148–4153
93. Scheller C, Ullrich A, McPherson K, Hefele B, Knoferle J, Lamla S, Olbrich AR, Stocker H, Arasteh K, ter Meulen V, Rethwilm A, Koutsilieri E, Dittmer U: CpG oligodeoxynucleotides activate HIV replication in latently infected human T cells. J Biol Chem 2004, 279(21):21897–21902
94. Paul G, Meissner W, Rein S, Harnack D, Winter C, Hosmann K, Morgenstern R, Kupsch A: Ablation of the subthalamic nucleus protects dopaminergic phenotype but not cell survival in a rat model of Parkinson's disease. Exp Neurol 2004, 185(2):272–280
95. Engelhorn C, Hoffmann F, Kurowski M, Stocker H, Kruse G, Notheis G, Belohradsky BH, Wintergerst U: Long-term pharmacokinetics of amprenavir in combination with delavirdine in HIV-infected children. AIDS 2004, 18(10):1473–1475
96. Dunay IR, Heimesaat MM, Bushrab FN, Muller RH, Stocker H, Arasteh K, Kurowski M, Fitzner R, Borner K, Liesenfeld O: Atovaquone maintenance therapy prevents reactivation of toxoplasmic encephalitis in a murine model of reactivated toxoplasmosis. Antimicrob Agents Chemother 2004, 48(12):4848–4854
97. Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, Katlama C, Stellbrink HJ, Delfraissy JF, Lange J, Huson L, DeMasi R, Wat C, Delehanty J, Drobnes C, Salgo M: Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. The New England journal of medicine 2003, 348(22):2186–2195
98. Gazzard BG, Pozniak AL, Rosenbaum W, Yeni GP, Staszewski S, Arasteh K, De Dier K, Peeters M, Woodfall B, Stebbing J, vant' Klooster GA: An open-label assessment of TMC 125--a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS 2003, 17(18):F49–54
99. Masuhr A, Mueller M, Simon V, Zwingers T, Kurowski M, Jessen H, Lauenroth-Mai E, Moll A, Schranz D, Moecklinghoff C, Arasteh K: Predictors of treatment failure during highly active antiretroviral therapy (racing trial). Eur J Med Res 2002, 7(8):341–346
100. Katlama C, Clotet B, Plettenberg A, Jost J, Arasteh K, Bernasconi E, Jeantils V, Cutrell A, Stone C, Purdon S: Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48-week data from a randomized, double-blind trial. HIV Med 2001, 2(1):27–34
101. Arasteh K, Wood R, Muller M, Prince W, Cass L, Moore KH, Dallow N, Jones A, Klein A, Burt V, Kleim JP: GW420867X administered to HIV-1-infected patients alone and in combination with lamivudine and zidovudine. HIV Clin Trials 2001, 2(4):307–316
102. Stocker H, Scheller C, Jassoy C: Destruction of primary CD4(+) T cells by cell-cell interaction in human immunodeficiency virus type 1 infection in vitro. J Gen Virol 2000, 81(Pt 8):1907–1911
103. Katlama C, Clotet B, Plettenberg A, Jost J, Arasteh K, Bernasconi E, Jeantils V, Cutrell A, Stone C, Ait-Khaled M, Purdon S: The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial. CNA3002 European Study Team. AIDS 2000, 14(7):781–789
104. Arasteh KN, Cordes C, Ewers M, Simon V, Dietz E, Futh UM, Brockmeyer NH, L'Age M P: HIV-related nontuberculous mycobacterial infection: incidence, survival analysis and associated risk factors. Eur J Med Res 2000, 5(10):424–430
105. Arasteh K, Hannah A: The role of vascular endothelial growth factor (VEGF) in AIDS-related Kaposi's sarcoma. Oncologist 2000, 5 Suppl 1:28–31
106. Stoehr A, Arasteh K, Staszewski S, Brockmeyer N, Albrecht H, Mertenskotter T, Jablonowski H, Emminger C, Rockstroh JK, Baumgarten R, Bogner J, Loch T, Plettenberg A: Pneumocystis carinii pneumonia in the Federal Republic of Germany in the era of changing antiretroviral therapy - IDKF 13 -. German AIDS Study Group (GASG/IdKF). Eur J Med Res 1999, 4(4):131–134
107. Migueletto BC, Neto AE, Domingues EZ, Neves de Castro PP, Stocker H, Marie SK, Meireles LP, Arai MH: Primary biliary cirrhosis and myopathy: an uncommon association. Rev Hosp Clin Fac Med Sao Paulo 1999, 54(5):165–168
108. Weiss R, Huhn D, Mitrou P, Nerl C, Schurmann D, Scheidegger C, Knauf W, Trenn G, Kronawitter U, Van Lunzen J, Arasteh K, Herbst H: HIV-related non-Hodgkin's lymphoma: CHOP induction therapy and interferon-alpha-2b/zidovudine maintenance therapy. Leuk Lymphoma 1998, 29(1-2):103–118
109. Stewart S, Jablonowski H, Goebel FD, Arasteh K, Spittle M, Rios A, Aboulafia D, Galleshaw J, Dezube BJ: Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol 1998, 16(2):683–691
110. Arasteh KN, Simon V, Musch R, Weiss RO, Przytarski K, Futh UM, Pleuger F, Huhn D, L'Age M P: Sensitivity and specificity of indirect immunofluorescence and Grocott-technique in comparison with immunocytology (alkaline phosphatase anti alkaline phosphatase = APAAP) for the diagnosis of Pneumocystis carinii in broncho-alveolar lavage (BAL). Eur J Med Res 1998, 3(12):559–563
111. Heise W, Arasteh K, Mostertz P, Skorde J, Schmidt W, Obst C, Koeppen M, Weiss R, Grosse G, Niedobitek F, L'Age M: Malignant gastrointestinal lymphomas in patients with AIDS. Digestion 1997, 58(3):218–224
112. Arasteh K, Cordes C, Futh U, Grosse G, Dietz E, Staib F: Co-infection by Cryptococcus neoformans and Mycobacterium avium intracellulare in AIDS. Mycopathologia 1997, 140(3):115–120
113. Bek B, Boeckh M, Lepenies J, Bieniek B, Arasteh K, Heise W, Deppermann KM, Bornhoft G, Stoffler-Meilicke M, Schuller I, Hoffken G: High-level sensitivity of quantitative pp65 cytomegalovirus (CMV) antigenemia assay for diagnosis of CMV disease in AIDS patients and follow-up. J Clin Microbiol 1996, 34(2):457–459
114. Arasteh K, Staib F, Grosse G, Futh U, L'Age M: Cryptococcosis in HIV infection of man: an epidemiological and immunological indicator? Zentralbl Bakteriol 1996, 284(2-3):153–163
115. Michel D, Marre E, Hampl W, Roczkos J, Muller S, Hertenstein B, Kern P, Heymer B, Salzberger B, Arasteh K, et al.: Intestinal cytomegalovirus disease in immunocompromised patients may be ruled out by search for cytomegalovirus DNA in stool samples. J Clin Microbiol 1995, 33(11):3064–3067
116. Jablonowski H, Arasteh K, Staszewski S, Ruf B, Stellbrink HJ, Schrappe M, Stoehr A, Haase W, Schomaker U, von Eisenhart Rothe B, et al.: A dose comparison study of didanosine in patients with very advanced HIV infection who are intolerant to or clinically deteriorate on zidovudine. German ddI Trial Group. AIDS 1995, 9(5):463–469
117. Arasteh K, L'Age M, Futh U, Grosse G, Staib F: CD4 lymphocyte count in HIV-positive persons exposed to Cryptococcus neoformans. Zentralbl Bakteriol 1995, 283(1):127–135
118. Albrecht H, Skorde J, Arasteh K, Heise W, Stellbrink HJ, Grosse G, L'Age M: Disseminated toxoplasmosis in AIDS patients--report of 16 cases. Scand J Infect Dis 1995, 27(1):71–74
119. Vohringer HF, Arasteh K: Pharmacokinetic optimisation in the treatment of Pneumocystis carinii pneumonia. Clin Pharmacokinet 1993, 24(5):388–412
120. Albrecht H, Stellbrink HJ, Arasteh K: Didanosine-induced disorders of glucose tolerance. Ann Intern Med 1993, 119(10):1050
121. Buhr M, Heise W, Arasteh K, Stratmann M, Grosse M, L'Age M: Disseminated toxoplasmosis with sepsis in AIDS. Clin Investig 1992, 70(12):1079–1081
122. Artigas J, Arasteh K, Averdunk R, Bachler B, Hornscheidt M, Grosse G, L'Age M, Niedobitek F: Hyaline globules reacting positively with zidovudine antibody in brain and spinal cord of AIDS patients. Lancet (London, England) 1991, 337(8750):1127–1128
